Free Trial
OTCMKTS:EKTAY

Elekta Q3 2026 Earnings Results & Report

Elekta logo
$6.23 +0.04 (+0.57%)
As of 11/11/2026 02:28 PM Eastern

Elekta reported Q3 2026 earnings on March 5, 2026. The company reported EPS of $0.09, while revenue was $433.29 million.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens

Elekta EPS Results

Actual EPS
$0.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Elekta Revenue Results

Actual Revenue
$433.29 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Elekta's next earnings date is estimated for Wednesday, November 25, 2026, based on past reporting schedules.

Conference Call Resources

Elekta Q3 2026 Earnings FAQ

Elekta (OTCMKTS:EKTAY) reported earnings of $0.09 per share for Q3 2026. The report was announced on Thursday, March 5, 2026.

Elekta reported revenue of $433.29 million for Q3 2026.

Elekta's next earnings date is estimated for Wednesday, November 25, 2026. MarketBeat tracks confirmed and estimated earnings dates for Elekta on the company's earnings history page.

Elekta Earnings Headlines

Elekta Announces Second-Quarter 2026/27 Results Presentation
Elekta (EKTAY) & Its Competitors Critical Contrast
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Elekta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elekta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elekta and other key companies, straight to your email.

About Elekta

Elekta (OTCMKTS:EKTAY) is a Swedish medical technology company that develops equipment and software for radiation therapy and other treatments used in cancer care and neurosurgery. Founded in 1972 by neurosurgeon Lars Leksell, the company builds on his work in stereotactic radiosurgery.

Its offerings include linear accelerators for external-beam radiation therapy, systems for stereotactic radiosurgery and brachytherapy, and software that helps healthcare providers plan and manage treatment. Elekta’s technologies are used by hospitals and clinics to deliver care for cancer and certain neurological conditions.

The company serves healthcare providers in markets around the world. Its work spans equipment, treatment-planning tools, and clinical information systems designed to support radiation oncology services.

View Elekta Profile